Literature DB >> 1584707

The effects of topical and oral L-selenomethionine on pigmentation and skin cancer induced by ultraviolet irradiation.

K E Burke1, G F Combs, E G Gross, K C Bhuyan, H Abu-Libdeh.   

Abstract

This study was conducted to determine whether oral and/or topical selenium (Se) supplementation can reduce the incidence of acute and/or chronic damage to the skin (i.e., sunburn and pigmentation and/or skin cancer, respectively) induced by ultraviolet (UV) irradiation in mice. Groups of 38 BALB:c female mice or 16 Skh:2 hairless pigmented mice were treated with 1) lotion vehicle, 2) 0.02% L-selenomethionine (SeMet) lotion, or 3) vehicle and 1.5 ppm SeMet in the drinking water. Within each group, 30 BALB:c mice or 12 Skh:2 mice were given UV irradiation (Westinghouse FS 40 bulbs) three times per week in doses of 0.575 and 0.24 J/cm2, respectively. The animals' weights and food intakes and the Se concentrations of skin and liver were measured. Skin biopsies were taken from the backs and abdomens of all animals to evaluate the relative amounts of Se and the damage by UV irradiation. Skin pigmentation was scored, and the total number of clinically detectable skin tumors per animal was counted weekly. Results showed that the skin Se concentrations in areas of application of the lotion containing SeMet were greater than those of animals given comparable oral doses, while the Se concentrations of untreated skin and liver were similar to those of animals receiving oral Se. Mice treated with Se showed no signs of toxicity and had significantly less skin damage by UV irradiation, as indicated by reduced inflammation and pigmentation and by later onset and lesser incidence of skin cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1584707     DOI: 10.1080/01635589209514180

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  9 in total

1.  Protection against ultraviolet radiation.

Authors:  A Hoffer
Journal:  CMAJ       Date:  1992-09-15       Impact factor: 8.262

Review 2.  Chemopreventive mechanisms of selenium.

Authors:  G F Combs
Journal:  Med Klin (Munich)       Date:  1999-10-15

3.  A prospective study of blood selenium levels and the risk of arsenic-related premalignant skin lesions.

Authors:  Yu Chen; Marni Hall; Joseph H Graziano; Vesna Slavkovich; Alexander van Geen; Faruque Parvez; Habibul Ahsan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-02       Impact factor: 4.254

4.  Subchronic oral toxicity studies of Se-methylselenocysteine, an organoselenium compound for breast cancer prevention.

Authors:  W D Johnson; R L Morrissey; I Kapetanovic; J A Crowell; D L McCormick
Journal:  Food Chem Toxicol       Date:  2007-11-12       Impact factor: 6.023

5.  Antioxidant capacities of the selenium nanoparticles stabilized by chitosan.

Authors:  Xiaona Zhai; Chunyue Zhang; Guanghua Zhao; Serge Stoll; Fazheng Ren; Xiaojing Leng
Journal:  J Nanobiotechnology       Date:  2017-01-05       Impact factor: 10.435

6.  Age-Dependent Protective Effect of Selenium against UVA Irradiation in Primary Human Keratinocytes and the Associated DNA Repair Signature.

Authors:  C Favrot; D Beal; E Blouin; M T Leccia; A M Roussel; W Rachidi
Journal:  Oxid Med Cell Longev       Date:  2018-02-22       Impact factor: 6.543

Review 7.  Enhancing Skin Health: By Oral Administration of Natural Compounds and Minerals with Implications to the Dermal Microbiome.

Authors:  David L Vollmer; Virginia A West; Edwin D Lephart
Journal:  Int J Mol Sci       Date:  2018-10-07       Impact factor: 5.923

8.  Selenium for the prevention of cutaneous melanoma.

Authors:  Pamela B Cassidy; Heidi D Fain; James P Cassidy; Sally M Tran; Philip J Moos; Kenneth M Boucher; Russell Gerads; Scott R Florell; Douglas Grossman; Sancy A Leachman
Journal:  Nutrients       Date:  2013-03-07       Impact factor: 5.717

9.  Outpatient Follow-up and Secondary Prevention for Melanoma Patients.

Authors:  Ryan G Gamble; Daniel Jensen; Andrea L Suarez; Anne H Hanson; Lauren McLaughlin; Jodi Duke; Robert P Dellavalle
Journal:  Cancers (Basel)       Date:  2010-06-07       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.